Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

Viking Therapeutics (VKTX) shares fell 14.5% after announcing a $275M common stock offering and $225M in convertible notes, upsized from an initial $400M plan. The move follows positive trial results for its weight-loss drug, VK2735, which is in Phase 3 trials.

Viking Therapeutics (VKTX) shares fell 15.61% after announcing an upsized equity offering of 7.85M shares at $35 each and $225M in convertible notes. The company plans to use proceeds for clinical development and general corporate purposes. The stock is still above key moving averages, with support at $31.50 and resistance at $36.50.

Viking Therapeutics (VKTX) shares fell 12% after pricing a $500 million raise, upsized from $400 million. The offering includes 7.86 million new shares at $35 each and $225 million in convertible notes. Proceeds will fund VK2735's development and commercialization. According to Morgan Stanley, the weight-loss drug market could be worth $150 billion by 2030.

Viking Therapeutics (VKTX) fell 15% after pricing a $500M upsized offering at $35.00 per share. Jaguar Health (JAGX) dropped 25% without a clear catalyst. Both moves are company-specific, as the biotech sector (IBB) rose 0.3% and the broader market (SPY) fell 0.3%.

Viking Therapeutics (VKTX) increased its stock offering to $225M, managed by Morgan Stanley and JPMorgan, priced at $35.00-$38.00 per share. The company, with no revenue and a $4.86B market cap, faces operational challenges and insider selling, but shows strong liquidity and momentum.

Viking Therapeutics (VKTX) expanded its stock offering to $225M, priced at $35-$38 per share. The company, unprofitable with no revenue, relies on equity financing for R&D. Its GF Score is 34/100, showing financial strength but weak profitability. Insiders sold $20.9M in shares over 12 months.